Manolete Partners PLC
08 September 2026
8 September 2026
Manolete Partners PLC
("Manolete" or the "Company")
AGM Trading Update
Positive trading in-line with expectations
Manolete (AIM:MANO), the UK's leading insolvency claims financing company, provides the following update on trading in the current financial year (FY27) ahead of its Annual General Meeting at 10:30am today.
The Group's trading performance has been positive and in-line with the Board's expectations for FY27. Realised revenues are ahead of the prior year, and the value of the Group's forward book has continued to increase, driven by growth in both the number and average value of new cases signed.
The Group intends to provide a more detailed update on trading for H1 in early October following the first half end, and will announce its Half Year Results as usual in November.
For further information please contact:
Manolete Partners
Mena Halton (Chief Executive Officer) via Houston
Will Sawyer (Chief Financial Officer)
Canaccord (NOMAD and Sole Broker) +44 (0)20 7523 8000
Stuart Andrews
Emma Gabriel
Harry Rees
Houston (Financial PR) +44 (0)77 3303 2695
Charlie Barker +44 (0)20 4529 0549
Nick Jackman
About Manolete Partners PLC
Manolete Partners Plc is the UK's leading insolvency claims financing company. Serving a growing market worth over £500 million annually, the Company has a highly experienced team with coverage across the UK and a proven track record of generating strong historic returns across over 1,400 cases financed and completed to date.
Widely recognised as the industry leader, Manolete is the only company in the insolvency litigation funding section to be ranked in Band 1 of the legal industry's prestigious Chambers Guide six times. The Company is also five-time winner of 'Insolvency Litigation Funder of the Year' at the Turnaround, Restructuring and Insolvency Industry Awards.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.